Article Versions Notes

Vanhoye X, Janin A, Caillaud A, Rimbert A, Venet F, Gossez M, Dijk W, Marmontel O, Nony S, Chatelain C, et al. APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants. International Journal of Molecular Sciences. 2022; 23(8):4281. https://doi.org/10.3390/ijms23084281

Vanhoye, Xavier, Alexandre Janin, Amandine Caillaud, Antoine Rimbert, Fabienne Venet, Morgane Gossez, Wieneke Dijk, Oriane Marmontel, Séverine Nony, Charlotte Chatelain, and et al. 2022. "APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants" International Journal of Molecular Sciences 23, no. 8: 4281. https://doi.org/10.3390/ijms23084281

Vanhoye, X., Janin, A., Caillaud, A., Rimbert, A., Venet, F., Gossez, M., Dijk, W., Marmontel, O., Nony, S., Chatelain, C., Durand, C., Lindenbaum, P., Rieusset, J., Cariou, B., Moulin, P., & Di Filippo, M. (2022). APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants. International Journal of Molecular Sciences, 23(8), 4281. https://doi.org/10.3390/ijms23084281